A time-resolved proteomic and prognostic map of COVID-19
Author
PA-COVID-19 Study group
Demichev, Vadim
Tober-Lau, Pinkus
Lemke, Oliver
Nazarenko, Tatiana
Thibeault, Charlotte
Whitwell, Harry
Röhl, Annika
Freiwald, Anja
Szyrwiel, Lukasz
Ludwig, Daniela
Correia-Melo, Clara
Aulakh, Simran Kaur
Helbig, Elisa T
Stubbemann, Paula
Lippert, Lena J
Grüning, Nana-Maria
Blyuss, Oleg
Vernardis, Spyros
White, Matthew
Messner, Christoph B
Joannidis, Michael
Sonnweber, Thomas
Klein, Sebastian J
Pizzini, Alex
Wohlfarter, Yvonne
Sahanic, Sabina
Hilbe, Richard
Schaefer, Benedikt
Wagner, Sonja
Mittermaier, Mirja
Machleidt, Felix
Garcia, Carmen
Ruwwe-Glösenkamp, Christoph
Lingscheid, Tilman
Bosquillon de Jarcy, Laure
Stegemann, Miriam S
Pfeiffer, Moritz
Jürgens, Linda
Denker, Sophy
Zickler, Daniel
Enghard, Philipp
Zelezniak, Aleksej
Campbell, Archie
Hayward, Caroline
Porteous, David J
Marioni, Riccardo E
Uhrig, Alexander
Müller-Redetzky, Holger
Zoller, Heinz
Löffler-Ragg, Judith
Attention
2299/24958
Abstract
COVID-19 is highly variable in its clinical presentation, ranging from asymptomatic infection to severe organ damage and death. We characterized the time-dependent progression of the disease in 139 COVID-19 inpatients by measuring 86 accredited diagnostic parameters, such as blood cell counts and enzyme activities, as well as untargeted plasma proteomes at 687 sampling points. We report an initial spike in a systemic inflammatory response, which is gradually alleviated and followed by a protein signature indicative of tissue repair, metabolic reconstitution, and immunomodulation. We identify prognostic marker signatures for devising risk-adapted treatment strategies and use machine learning to classify therapeutic needs. We show that the machine learning models based on the proteome are transferable to an independent cohort. Our study presents a map linking routinely used clinical diagnostic parameters to plasma proteomes and their dynamics in an infectious disease.